AgomAb Therapeutics NV ADR(AGMB) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:00 PM ET (Korea 10/31 05:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | 25.98% | Shs Outstand | 48.7M | Perf Week | -17.24% |
| Market Cap | 0.37B | Forward P/E | - | EPS next Y | -17.49% | Insider Trans | 0.36% | Shs Float | 36.5M | Perf Month | -13.41% |
| Enterprise Value | 0.08B | PEG | - | EPS next Q | -0.34 | Inst Own | 26.78% | Short Float | 2.58% | Perf Quarter | -44.6% |
| Income | - | P/S | - | EPS this Y | 98.91% | Inst Trans | 0.13% | Short Ratio | 6.48 | Perf Half Y | -33.07% |
| Sales | - | P/B | 1.22 | EPS next 5Y | 76.3% | ROA | - | Short Interest | 0.94M | Perf YTD | -49.05% |
| Book/sh | 6.16 | P/C | 1.28 | EPS past 3/5Y | -102.05% - | ROE | - | 52W High | -57.97% ($17.82) | Perf Year | - |
| Cash/sh | 5.85 | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 0.54% ($7.45) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | - | Gross Margin | - | Volatility(W/M) | 12.01% 8.95% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.84 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 12.88 | EPS Q/Q | - | Profit Margin | - | RSI (14) | 29.2 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 12.88 | Sales Q/Q | - | SMA20 | -13.2% ($8.63) | Beta | - | Target Price | $37.95 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/6 | SMA50 | -31.41% ($10.92) | Rel Volume | 1.36 | Prev Close | $7.95 |
| Employees | 62 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -177.84% - | SMA200 | -38.13% ($12.11) | Avg Volume(3M) | 0.15M | Price | $7.49 |
| IPO | 2026/2/6 | Option/Short | No/Yes | Trades | 1123 | Volume | 197,838 | Change | -5.79% |
🧬 This is a clinical-stage biopharmaceutical company targeting fibrosis (fibrosis). It develops novel drug candidates aimed at fibrosis and regeneration pathways in organs, with its pipeline concentrated on areas of significant unmet medical need, including fibrotic strictures in Crohn's disease, idiopathic pulmonary fibrosis, and liver cirrhosis. It is a clinical-stage biotech currently pursuing a recent listing on Nasdaq.
Over the past 1 year, on the lower side
58% below its 1-year high.
Traded more than usual. That is 136% of its average volume.
Earnings are growing steadily
Earnings are expected to grow by +98.9% this year.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Long-term returns are roughly flat
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 26.8%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
SBIO ALPS Medical Breakthroughs ETF <0.01% It ranks #246 of 597 in the industry
Based on market cap of $369M.
RLMD#243 Relmada Therapeutics Inc $382M PER - 
TRXB#244 Trex Bio Inc $377M PER - 
CAPR#245 Capricor Therapeutics Inc $371M PER - AGMB#246 AgomAb Therapeutics NV ADR $369M PER - 
FENC#247 Fennec Pharmaceuticals Inc $359M PER - 
FAQ
What kind of company is AGMB?
AGMB belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of AGMB?
The market cap of AGMB is approximately $369M, ranking 3,405 within its sector.
What is the 52-week high and low for AGMB?
AGMB has recorded a 52-week high of $17.82 and a low of $7.45.
